These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12581567)

  • 41. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of FDG-PET in the management of non-small cell lung carcinoma.
    Ho Shon IA; Maisey MN
    Ann Acad Med Singap; 2004 Mar; 33(2):166-74. PubMed ID: 15098629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
    Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
    Deuschl C; Nensa F; Grueneisen J; Poeppel TD; Sawicki LM; Heusch P; Gramsch C; Mönninghoff C; Quick HH; Forsting M; Umutlu L; Schlamann M
    Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer.
    Bury T; Dowlati A; Paulus P; Corhay JL; Hustinx R; Ghaye B; Radermecker M; Rigo P
    Eur Respir J; 1997 Nov; 10(11):2529-34. PubMed ID: 9426090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.
    Chiu CH; Yeh YC; Lin KH; Wu YC; Lee YC; Chou TY; Tsai CM
    J Thorac Oncol; 2011 Oct; 6(10):1697-703. PubMed ID: 21869716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
    Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
    Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
    Li X; Zhang H; Xing L; Xu X; Xie P; Ma H; Zhang L; Chen M; Sun X; Xu W; Chen L; Yu J
    Clin Lung Cancer; 2013 Sep; 14(5):568-73. PubMed ID: 23835164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
    J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.